A systematic review pooling data from 14 randomized trials involving over 100,000 participants confirms both safety and efficacy of respiratory syncytial virus (RSV) vaccines. Published in the Cochrane Database, the analysis validates RSV vaccination as a robust defense against this common respiratory infection, particularly benefiting vulnerable populations. These findings support broader RSV vaccine adoption in public health immunization programs.